B. Riley Wealth Advisors Inc. Sells 525 Shares of Exact Sciences Co. (NASDAQ:EXAS)

B. Riley Wealth Advisors Inc. lessened its position in Exact Sciences Co. (NASDAQ:EXAS) by 13.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,304 shares of the medical research company’s stock after selling 525 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Exact Sciences were worth $244,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Wolff Wiese Magana LLC grew its holdings in Exact Sciences by 459.5% in the 4th quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after acquiring an additional 340 shares during the last quarter. Able Wealth Management LLC purchased a new stake in shares of Exact Sciences in the 4th quarter worth about $45,000. National Bank of Canada FI lifted its position in shares of Exact Sciences by 30.9% in the 4th quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock worth $63,000 after purchasing an additional 200 shares during the period. Quest Partners LLC purchased a new stake in shares of Exact Sciences in the 4th quarter worth about $66,000. Finally, Desjardins Global Asset Management Inc. lifted its position in shares of Exact Sciences by 40.9% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 903 shares of the medical research company’s stock worth $67,000 after purchasing an additional 262 shares during the period. Institutional investors own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In related news, CEO Kevin T. Conroy sold 1,155 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total value of $69,473.25. Following the transaction, the chief executive officer now owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the sale, the executive vice president now owns 71,787 shares of the company’s stock, valued at approximately $5,025,090. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin T. Conroy sold 1,155 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the sale, the chief executive officer now directly owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The disclosure for this sale can be found here. Insiders sold 3,498 shares of company stock valued at $230,105 in the last three months. 1.36% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on EXAS shares. BTIG Research dropped their target price on shares of Exact Sciences from $80.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday. Citigroup dropped their target price on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Canaccord Genuity Group lowered their price target on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Scotiabank initiated coverage on shares of Exact Sciences in a research report on Thursday. They set a “sector outperform” rating and a $70.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on shares of Exact Sciences in a research report on Monday, June 3rd. They set a “buy” rating and a $75.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $87.86.

Exact Sciences Trading Up 0.7 %

NASDAQ EXAS opened at $44.49 on Friday. The company’s 50-day moving average price is $50.78 and its 200-day moving average price is $60.41. The company has a current ratio of 1.64, a quick ratio of 1.45 and a debt-to-equity ratio of 0.66. The stock has a market cap of $8.21 billion, a PE ratio of -33.70 and a beta of 1.26. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $100.77.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). The firm had revenue of $637.52 million for the quarter, compared to analysts’ expectations of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. Equities research analysts forecast that Exact Sciences Co. will post -1.15 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.